ライフサイエンスコーパス: neoplasm

1 -CHT arm developed a therapy-related myeloid neoplasm.

2 ith AID with the risk for developing myeloid neoplasm.

3 ransplantation model for a human histiocytic neoplasm.

4 tionale to target infiltrating cells in this neoplasm.

5 enesis, invasion, metastasis of human breast neoplasm.

6 in 1.5-5% of patients with a neuroendocrine neoplasm.

7 f the same neoplasm or an independent second neoplasm.

8 as associated with a 7-fold risk for myeloid neoplasm.

9 th nerve palsy owing to a known intracranial neoplasm.

10 with histiocytosis for a concomitant myeloid neoplasm.

11 r in children, hepatoblastoma (HB) is a rare neoplasm.

12 favouring the diagnosis of AH over pituitary neoplasm.

13 resent a new aggressive variant of this rare neoplasm.

14 t may foreshadow the development of an overt neoplasm.

15 ore the diagnosis of therapy-related myeloid neoplasm.

16 atient developed tuberculosis or a malignant neoplasm.

17 with the incidence in development of myeloid neoplasm.

18 n 18 years or who had an abdominal malignant neoplasm.

19 the association between diet and colorectal neoplasms.

20 %) benign neoplasms, and 18 (3.2%) malignant neoplasms.

21 esis, evolution, and complexity of mast cell neoplasms.

22 relationship between Alzheimer's disease and neoplasms.

23 t mature T-cell and natural killer (NK) cell neoplasms.

24 11 mice given the control vector, developed neoplasms.

25 luding neurocognitive deficits and secondary neoplasms.

26 rs in the pathogenesis of myeloproliferative neoplasms.

27 42H-expressing mice rapidly developed T cell neoplasms.

28 yroid hormone (PTH) secretion in parathyroid neoplasms.

29 nal tumours and uterine benign and malignant neoplasms.

30 ry cell leukemia and a number of histiocytic neoplasms.

31 d risk of developing therapy-related myeloid neoplasms.

32 ytic cells during infection, autoimmunity or neoplasms.

33 -eight patients (52%) had myeloproliferative neoplasms.

34 (PA) is one of the most common intracranial neoplasms.

35 sed in 54 individuals as benign or malignant neoplasms.

36 prominent oncogenic driver of hematopoietic neoplasms.

37 seases, central nervous system diseases, and neoplasms.

38 d risk of developing therapy-related myeloid neoplasms.

39 the pathogenetic basis of myeloproliferative neoplasms.

40 of eosinophilia-associated TK fusion-driven neoplasms.

41 d risk of developing therapy-related myeloid neoplasms.

42 t risk of developing therapy-related myeloid neoplasms.

43 order to determine the relationship between neoplasms.

44 into the routine diagnostic work-up of these neoplasms.

45 aired megakaryopoiesis in myeloproliferative neoplasms.

46 nderstanding of the natural history of these neoplasms.

47 ignificantly reduced the growth of implanted neoplasms.

48 patients with Intraductal Papillary Mucinous Neoplasms.

49 ctivated in the context of proliferation and neoplasms.

50 e of the highly infiltrative nature of these neoplasms.

51 fusions in pigment-synthesizing melanocytic neoplasms.

52 o the development of therapy-related myeloid neoplasms.

53 ating the developmental origins of pediatric neoplasms.

54 multiple myeloma (MM) and other late B-cell neoplasms.

55 onal treatment options for people with these neoplasms.

56 pecific poxvirus that causes persistent skin neoplasms.

57 in the clinical management of hematological neoplasms.

58 t CALR-MPL interaction in myeloproliferative neoplasms.

59 me of these cases as eosinophilia-associated neoplasms.

60 (BCCs), are the most common human malignant neoplasms.

61 expression is lost in numerous mature B-cell neoplasms.

62 nt neoplasms compared with E2f7/8-proficient neoplasms.

63 and metastases are far commoner than primary neoplasms.

64 ssification and grading of these distinctive neoplasms.

65 but did not develop therapy-related myeloid neoplasms.

66 openic patients with hematological malignant neoplasms?

67 Subsequent neoplasm 15-year cumulative incidence, cumulative burden

68 s while the most common GBD categories were "Neoplasms" (22.8 %) and "Diabetes" (8.9 %).

69 causes, including 746 deaths from subsequent neoplasms, 241 from cardiac causes, 137 from pulmonary c

70 sed mature lymphomas, 321 precursor lymphoid neoplasms, 314 myeloid disorders, and 200 nonhematopoiet

71 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/MPN) and 3 pati

72 Sound knowledge of neoplasms affecting the sternum and their imaging appear

73 and did not develop therapy-related myeloid neoplasms after at least 5 years of follow-up.

74 7%) of 288 patients with other periampullary neoplasms also had a deleterious germline mutation.

75 e undescribed frequent occurrence of myeloid neoplasms among patients with ECD and MH.

76 ed and point-of-care) FITs detected advanced neoplasms (AN) in a single colorectal cancer screening s

77 atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three di

78 rpretation of guidelines, proportions of any neoplasm and malignant neoplasm, respectively, were 1% a

79 ng when it was an option, proportions of any neoplasm and malignant neoplasm, respectively, were 1% a

80 act mechanism by which asbestos induces this neoplasm and other asbestos-related diseases is still no

81 s the development of therapy-related myeloid neoplasm and the primary exposure was CHIP.

82 een individuals with therapy-related myeloid neoplasm and those without, suggesting that mutation-spe

83 e WHO classification of lymphoid and myeloid neoplasms and acute leukemia was released in 2016.

84 ique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene

85 update of the WHO classification of myeloid neoplasms and AML, and mutations in three genes- RUNX1,

86 GBM is among the most neovascularised neoplasms and its malignant progression associates with

87 n the diagnostic algorithm of neuroendocrine neoplasms and its overall utility in their management.

88 tions have refined classification of myeloid neoplasms and major forms of lymphomas arising from B, T

89 Predictors of neoplasms and malignancy were evaluated by using multiva

90 f summary of theranostics for neuroendocrine neoplasms and metastatic castration-refractory prostate

91 ysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, have the potent

92 tic changes influence risk of adult lymphoid neoplasms and suggest a difference in this association b

93 e functioning is a common result of cerebral neoplasms and treatment, although there is substantial h

94 cancer, diverticular disease, benign colonic neoplasm, and ulcerative colitis/regional enteritis were

95 equently developed a therapy-related myeloid neoplasm, and were 70 years or older at either diagnosis

96 3.3%) nonneoplastic cysts, 77 (13.5%) benign neoplasms, and 18 (3.2%) malignant neoplasms.

97 breast neoplasms, colorectal neoplasms, lung neoplasms, and 32 other diseases demonstrated the abilit

98 ents with other pancreatic and periampullary neoplasms, and 51 patients with non-neoplastic diseases

99 bsequently developed therapy-related myeloid neoplasms, and had available paired samples of bone marr

100 mphoma, Hodgkin lymphoma, myeloproliferative neoplasms, and myelodysplastic syndrome.

101 e adaptive immune system, the development of neoplasms, and the persistence of pathogens despite drug

102 rome, one biliary tract infection, one other neoplasms, and two colonic perforations) and one died du

103 adaptive response to specific infections or neoplasms, antigen-presenting cells (APC) and effector T

104 Therapy-related myeloid neoplasms are a potentially life-threatening consequence

105 Patients with myeloid neoplasms are at variable risk of vascular complications

106 Therapy-related myeloid neoplasms are secondary malignancies that are often fata

107 , and to determine genomic features of three neoplasms arising in two of these patients.

108 flammatory bowel disease or gastrointestinal neoplasm as a cause of chronic diarrhea.

109 symporter in thyroid cancer and nonthyroidal neoplasms as well as a brief summary of theranostics for

110 In neoplasms, ASL is of particular interest in cases in whi

111 ll histiocytosis (LCH) is a rare histiocytic neoplasm associated with somatic mutations in the genes

112 Mucinous cystic neoplasm-associated adenocarcinoma appears to have decre

113 ulative incidence of therapy-related myeloid neoplasms at 10 years was significantly higher in patien

114 mon in patients with therapy-related myeloid neoplasms at the time of their primary cancer diagnosis

115 mon in patients with therapy-related myeloid neoplasms at the time of their primary cancer diagnosis

116 The expected number of hematopoietic neoplasms based on The Netherlands Cancer Registry data

117 f branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

118 ls mediate resistance against haematopoietic neoplasms but are generally considered to play a minor r

119 assessed relative rates (RRs) of subsequent neoplasms by 5-year increments, adjusting for demographi

120 pact of parental age on the risk of lymphoid neoplasms by subtype.

121 enchyma and by the formation of benign renal neoplasms called angiolipomas.

122 Solid neoplasms can be directly responsible for organ failures

123 g those >60 years of age, subsequent primary neoplasms, cardiac disease, and other circulatory condit

124 who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these

125 who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these

126 yelofibrosis is a chronic myeloproliferative neoplasm characterised by splenomegaly, cytopenias, bone

127 Colorectal neoplasms [colorectal cancer (CRC) and colorectal advanc

128 A detailed case study on breast neoplasms, colorectal neoplasms, lung neoplasms, and 32

129 al branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms.

130 ent myeloid cells induces pulmonary LCH-like neoplasms composed of pathogenic CD11c(high)F4/80(+)CD20

131 (+/-) mice, at 18 months of age, had uterine neoplasms comprising squamous metaplasia, adenofibroma a

132 ases) and patients who did not develop these neoplasms (controls).

133 ases) and patients who did not develop these neoplasms (controls).

134 ate that risk of serrated pathway colorectal neoplasms could be reduced with lifestyle changes.

135 ssification and grading of these distinctive neoplasms.Deep penetrating nevi (DPN) are unusual melano

136 n (WHO) classification of myeloproliferative neoplasms defines 2 stages of primary myelofibrosis (PMF

137 lignancies (high-grade dysplasia or invasive neoplasm) developed after 5 years in 20 of 363 patients

138 ncreased the risk of therapy-related myeloid neoplasm development (hazard ratio 13.7, 95% CI 1.7-108.

139 nal haemopoiesis and therapy-related myeloid neoplasm development, we also analysed the prevalence of

140 we identified 32,000 patients with lymphoid neoplasms, diagnosed at ages 0-79 years during the perio

141 row from the time of therapy-related myeloid neoplasm diagnosis and peripheral blood from the time of

142 d by the time of the therapy-related myeloid neoplasm diagnosis.

143 s; the highest AERs were found for malignant neoplasms, diseases of digestive organs, and diseases of

144 -2.49; P < .001), and not having a malignant neoplasm (eg, BRCA carriers) (OR, 3.13; 95% CI, 1.25-7.8

145 Diverse neoplasms encountered were found prospectively in 22%.

146 When analyzed by type of malignant neoplasm, ERCP was associated with a lower rate of adver

147 ans cell histiocytosis (LCH) and the non-LCH neoplasm Erdheim-Chester disease (ECD) are heterogeneous

148 Malignant neoplasms evolve in response to changes in oncogenic sig

149 imaging modalities in detecting of prostatic neoplasm, followed by MRI, and then by TRUS.

150 hemangioma is a locally aggressive vascular neoplasm, found in bones and soft tissue, whose cause is

151 Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with >/=4 crit

152 estionnaire to patients who underwent PD for neoplasms from 1998 to 2011 and compared their scores wi

153 who did not develop therapy-related myeloid neoplasms had clonal haemopoiesis.

154 ditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

155 ral history of PDGFRA- and PDGFRB-rearranged neoplasms has been dramatically altered by imatinib.

156 llary mucinous neoplasms and mucinous cystic neoplasms, have the potential to progress to pancreatic

157 ion was associated with a myeloproliferative neoplasm (hazard ratio, 8.18; 95% confidence interval: 1

158 increase in incidence of offspring lymphoid neoplasms (hazard ratio = 1.03, 95% confidence interval:

159 st line investigation for detecting prostate neoplasms, hence USG (TRUS) remains the first line inves

160 idence interval (CI): 1.03, 1.07), malignant neoplasms (HR = 1.06, 95% CI: 1.03, 1.09), lung cancer (

161 ulative incidence of therapy-related myeloid neoplasms in both cases and controls at 5 years was sign

162 Vascular tumors are among the most common neoplasms in infants and children; 5%-10% of newborns pr

163 nd smoking, and the development of malignant neoplasms in kidney transplant recipients.

164 r development of metachronous or synchronous neoplasms in patients with IPMN.

165 er treatments are associated with subsequent neoplasms in survivors of childhood cancer.

166 creased risk to develop subsequent high-risk neoplasms in the remnant pancreas.

167 sequencing, the pathogenesis of plasma cell neoplasms in these mice is not linked to activation of a

168 , histologic, and clinical differences, with neoplasms in this group ranging from low to high grade.

169 mprise a diverse set of lymphoid and myeloid neoplasms in which normal hematopoiesis has gone awry an

170 en implicated in the pathobiology of several neoplasms including diffuse large B-cell lymphoma (DLBCL

171 , 1639 survivors experienced 3115 subsequent neoplasms, including 1026 malignancies, 233 benign menin

172 ing of the molecular pathogenesis of myeloid neoplasms, including acute myeloid leukemia (AML), has b

173 rk anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic lymphocytic leukemia

174 gle PGCCs grew into a wide spectrum of human neoplasms, including germ cell tumors, high-grade and lo

175 es to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung canc

176 ersely, BRAF-V600E is absent in other B-cell neoplasms, including mimickers of HCL that require diffe

177 As found in other myeloproliferative neoplasms, increased production of profibrogenic and ang

178 Genomic analysis of mouse neoplasms induced by the Dnajb1-Prkaca fusion revealed a

179 lastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA (miRNA)-based biom

180 patients with intraductal papillary mucinous neoplasm (IPMN).

181 or pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-generation sequenci

182 s/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grade intraep

183 of pancreatic intraductal papillary mucinous neoplasms (IPMN).

184 sors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their pathology/hist

185 criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main duct (MD IPMNs) or

186 phic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are identified with in

187 ite profiling supported the observation that neoplasm is triggered by a decrease in hDBR1 expression

188 patients who develop therapy-related myeloid neoplasms is unknown.

189 d case study on breast neoplasms, colorectal neoplasms, lung neoplasms, and 32 other diseases demonst

190 tion of outcomes (nonneoplastic cyst, benign neoplasm, malignant neoplasm) was compared in each ratin

191 At diagnosis or relapse of most hematologic neoplasms, malignant cells are often easily accessible i

192 Non-Hodgkin lymphoma comprises a variety of neoplasms, many of which arise from germinal center (GC)

193 Pancreatic mucinous cystic neoplasms (MCNs) harbor malignant potential, and current

194 gistry, the expected number of hematopoietic neoplasms (MDS, AML, MPN, and MDS/MPN) was calculated an

195 ed an increase in excess life-years lost for neoplasms (men: 0.7; women: 0.4), heart diseases (men: 1

196 S with >/=4 criteria suggestive of a myeloid neoplasm (MHES; n =10), or steroid-refractory PDGFRA-neg

197 atients with ECD have an overlapping myeloid neoplasm, most commonly occurring as a myeloproliferativ

198 dysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) for which no current standard of care exi

199 ic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated.

200 dysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocy

201 Myeloproliferative neoplasm (MPN) patients frequently show co-occurrence of

202 mediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemi

203 e myeloid leukemia (AML), myeloproliferative neoplasm (MPN), MDS/MPN, or otherwise unexplained cytope

204 t commonly occurring as a myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or mixed

205 d in most patients with a myeloproliferative neoplasm (MPN).

206 and molecular biology of myeloproliferative neoplasms (MPN) remains incompletely understood.

207 nagement of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibro

208 PCM1-JAK2" In addition to myeloproliferative neoplasms (MPN), these patients can present with myelody

209 lphia chromosome-negative myeloproliferative neoplasms (MPNs) and JAK2 V617F clonal hematopoiesis in

210 Myeloproliferative neoplasms (MPNs) are a group of related clonal hematolog

211 Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoiet

212 Myeloproliferative neoplasms (MPNs) arise in the hematopoietic stem cell (H

213 elphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essenti

214 Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or

215 lphia chromosome-negative myeloproliferative neoplasms (MPNs), is unknown.

216 splastic syndromes (MDS), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classical H

217 present in patients with myeloproliferative neoplasms (MPNs), the risk of AMD in these patients may

218 of JAK/STAT signaling in myeloproliferative neoplasms (MPNs).

219 oid malignancies, such as myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid

220 Uterine neoplasms, myometria and jaw bones of Cdc73(+/-) mice ha

221 Neuroendocrine neoplasms (NEN) are rare neoplasms that originate from n

222 icism in the APC gene in patients with colon neoplasms not associated with any other genetic variants

223 y diagnosis and treatment is prudent in such neoplasms not only to halt disease progression but also

224 , with most patients with myeloproliferative neoplasm now having a biological basis for their excessi

225 Neoplasms occurred in 0.5% of the patients treated with

226 Neoplasms occurred in 2.3% of patients who received ocre

227 te regression, SRU rating predicted both any neoplasm (odds ratio, 2.58; P < .0001) and malignant neo

228 (odds ratio, 2.58; P < .0001) and malignant neoplasm (odds ratio, 4.94; P = .005).

229 independent prognostic factor for malignant neoplasms (odds ratio, 12.76; 95% CI, 2.43-66.88; P = .0

230 second most common solid pediatric malignant neoplasm of bone and soft tissue.

231 yomatosis (LAM) is a progressive destructive neoplasm of the lung associated with inactivating mutati

232 participate in the development of malignant neoplasms of keratinocytes.

233 d data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 years in po

234 ll tumors are the most frequent interstitial neoplasms of the testis with increased incidence in rece

235 4 patients developed therapy-related myeloid neoplasms, of whom four (80%) had clonal haemopoiesis; 1

236 encing for 120 genes associated with myeloid neoplasms on megakaryocytes isolated from aspirated bone

237 senchymal component that represents a second neoplasm or (benign) reactive process.

238 rogression represents recurrence of the same neoplasm or an independent second neoplasm.

239 whereas patients with hematologic malignant neoplasms or less severe illness seem to benefit from lo

240 or acute lymphoblastic leukemia, plasma cell neoplasms, or diffuse large B-cell lymphoma.

241 essed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable

242 reases in the rates of death from subsequent neoplasm (P<0.001), cardiac causes (P<0.001), and pulmon

243 lesions, known as pancreatic intraepithelial neoplasms (PanIN), and describe a unique subpopulation o

244 9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02).

245 cancer occurring as first primary malignant neoplasm (PM) by age.

246 ruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anaemia (nine [4%]).

247 inib, including eight patients who died from neoplasm progression.

248 alth Organization classification of lymphoid neoplasms recently acknowledged the complexity of this d

249 proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non- intraduc

250 pathway contributes to oncogenesis in human neoplasms remain poorly understood.

251 s, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU 0, 17% and

252 n, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU 0, 17% and

253 e mutations in the histiocytosis and myeloid neoplasm resulted in discordant and adverse responses to

254 ences might exist in therapy-related myeloid neoplasm risk.

255 l changes in treatment dosing and subsequent neoplasm risk.

256 py are associated with changes in subsequent neoplasm risk.

257 whom paired CHIP and therapy-related myeloid neoplasm samples were available, the mean allele frequen

258 whom paired CHIP and therapy-related myeloid neoplasm samples were available.

259 e at increased risk for subsequent malignant neoplasms (SMNs).

260 Second neoplasms, spinal disorders, and pulmonary disease were

261 reased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cance

262 etected hallmark driver mutations of myeloid neoplasms (such as JAK2V617F and CALR mutations) coexist

263 ancers, it also has activity against myeloid neoplasms, such as Erdheim-Chester disease (ECD).

264 inuing decrease in the rates of other common neoplasms, such as lung and stomach since mid-1980s, pro

265 y the same method failed to develop LCH-like neoplasms, suggesting that each oncogene may initiate pu

266 y gynecological cancer and unlike most other neoplasms, survival rates for OC have not significantly

267 is (LAM) is a rare, low-grade, metastasizing neoplasm that arises from an unknown source, spreads via

268 mia (JMML) is a pediatric myeloproliferative neoplasm that bears distinct characteristics associated

269 Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after trea

270 urkitt lymphoma (BL) is an aggressive B-cell neoplasm that is currently treated by intensive chemothe

271 nerve sheath tumors (MPNSTs) are aggressive neoplasms that commonly occur in patients with neurofibr

272 e models for parathyroid tumours and uterine neoplasms that develop in the HPT-JT syndrome, provide i

273 Neuroendocrine neoplasms (NEN) are rare neoplasms that originate from neuroendocrine cells and a

274 Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening,

275 collectively termed therapy-related myeloid neoplasm (TMN), and other adverse outcomes.

276 munity in a variety of diseases ranging from neoplasms to viral infection.

277 ndocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and treated on the basis o

278 relative risk for developing a hematopoietic neoplasm was 2.7.

279 me from onset of AID to diagnosis of myeloid neoplasm was 8 (interquartile range, 4-15) years.

280 ollow-up and in whom a new primary malignant neoplasm was detected.

281 rum CA19-9 level for patients with malignant neoplasms was 210 vs 15 U/mL for those without (P = .001

282 Diagnostic accuracy for malignant neoplasms was highest at an MPD diameter cutoff of 7.2 m

283 nneoplastic cyst, benign neoplasm, malignant neoplasm) was compared in each rating group by using the

284 licular adenoma, a benign subtype of thyroid neoplasm, was also found to harbor mutations (12/29, 41%

285 n the ICU for organ failure related to solid neoplasms were included.

286 rs often are associated with mucinous cystic neoplasms, which are hypothesized to share a histogenic

287 Pancreatic cancer is a malignant neoplasm with a high mortality rate.

288 kemia (CNL) is a distinct myeloproliferative neoplasm with a high prevalence (>80%) of mutations in t

289 rare and aggressive cutaneous neuroendocrine neoplasm with a high risk of recurrence following resect

290 ll leukemia (HCL) is a chronic mature B-cell neoplasm with unique clinicopathologic features and an i

291 MML) is a myelodysplastic/myeloproliferative neoplasm with variable clinical course.

292 GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging fr

293 ganization (WHO) category, "Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA,

294 s in dissecting the genetic basis of myeloid neoplasms with eosinophilia.

295 Melanocytic neoplasms with prominent pigment synthesis mimicking equ

296 netrating nevi (DPN) are unusual melanocytic neoplasms with unknown genetic drivers.

297 Sarcomas include diverse mesenchymal neoplasms with widely varied prognosis, clinical behavio

298 myeloid disorders, and 200 nonhematopoietic neoplasms, with 4,390 benign lesions.

299 e detection in selected myeloid and lymphoid neoplasms, with a focus on the current and future role o

300 ew of cell populations comprising a prostate neoplasm, yielding novel genomic measures with the poten